发明名称 |
Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders |
摘要 |
This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders. |
申请公布号 |
AU3625500(A) |
申请公布日期 |
2000.09.28 |
申请号 |
AU20000036255 |
申请日期 |
2000.03.10 |
申请人 |
DU PONT PHARMACEUTICALS COMPANY |
发明人 |
PANCRAS C. WONG;SHAKER A. MOUSA |
分类号 |
C07D261/10;A61K31/222;A61K31/4015;A61K31/402;A61K31/42;A61K31/422;A61K31/445;A61K31/4465;A61K31/60;A61K31/616;A61K31/715;A61K31/727;A61K38/00;A61K38/46;A61K39/395;A61K45/00;A61K45/06;A61P7/02;A61P9/00;A61P9/08;A61P9/10;C07K16/28 |
主分类号 |
C07D261/10 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|